ArticleJournal of managed care & specialty pharmacy2025

Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.

Karl M Kilgore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.